Eli Lilly (LLY) PT Raised to $920 at BMO Capital

BMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $920.00 (from $900.00) while maintaining an Outperform rating.

The analyst commented: "With Ph 3 ATTAIN 1 and 2 trials set to read out in 3Q25, Lilly's orforglipron is on the cusp of moving commercial. ATTAIN-1 data is likely to read out in early/mid-August, potentially closely followed by ATTAIN-2. We expect orforglipron will be able to demonstrate >15% weight loss in ATTAIN-1, although tolerability may deteriorate slightly relative to ACHIEVE-1. We expect LLY shares could trade up 7-10% on positive data, pressuring NVO/AMGN. As a result of our increased confidence in orforglipron, we have raised our estimates; target to $920."

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
• Cerebras Systems (CBRS) PT Lowered to $300 at Mizuho